Hannah Mamuszka, CEO of Alva10 tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation. The promise of value-based pricing, though, is still very much alive. The key, she says, lies in restructuring the relationship between the diagnostics providers and the payors.